Pyridazine, as a privileged scaffold, has been extensively utilized in drug development due
to its multiple biological activities. Especially around its distinctive anticancer property, a …

The search for molecules to be targeted that are involved in apoptosis resistance/increased
survival and pathogenesis of onco-hematological malignancies is ongoing since these …

Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and
greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has …

The design of kinase inhibitors targeting the oncogenic kinase BCR-ABL constitutes a
promising paradigm for treating chronic myeloid leukaemia (CML). Nevertheless, the …

BCR-ABL inhibition is an effective therapeutic approach for the treatment of chronic myeloid
leukaemia (CML). Herein, we report the discovery of AKE-72 (5), a diarylamide 3 …

Four afatinib derivatives were designed and modeled. These derivatives were compared to
the known tyrosine-kinase inhibitors in treating Chronic Myeloid Leukemia, ie, imatinib and …

Despite significant progress in oncology therapeutics, cancer remains a leading cause of
mortality worldwide. Chronic myeloid leukemia, which accounts for 15% of all adult leukemia …

This scholarly investigation presents pioneering drug candidates for combating leukemia,
distinguished by reduced side effects and elevated efficacy. The study focuses on azo …

Drug resistance and lack of specificity of currently available chemotherapeutics for cancer
cells contribute to the failure of cancer chemotherapy. This highlights the pressing need to …

BACKGROUND: As in other malignancies, different subsets of natural killer (NK) cells play a
crucial role in the recognition and lysing of malignant cells in chronic myeloid leukemia …